Analysts expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will report $8.51 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $10.00 million and the lowest estimate coming in at $6.13 million. Conatus Pharmaceuticals posted sales of $8.80 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.3%. The firm is expected to announce its next earnings report on Wednesday, March 6th.
According to Zacks, analysts expect that Conatus Pharmaceuticals will report full year sales of $34.81 million for the current fiscal year, with estimates ranging from $32.30 million to $36.18 million. For the next fiscal year, analysts expect that the business will post sales of $46.87 million, with estimates ranging from $25.32 million to $80.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $7.67 million for the quarter, compared to analysts’ expectations of $9.70 million. Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%.
Conatus Pharmaceuticals stock traded down $0.41 during mid-day trading on Tuesday, hitting $5.32. The stock had a trading volume of 15,019 shares, compared to its average volume of 623,252. The stock has a market cap of $156.76 million, a price-to-earnings ratio of -8.69 and a beta of 1.84. Conatus Pharmaceuticals has a 12 month low of $3.22 and a 12 month high of $7.95. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 0.83.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its holdings in Conatus Pharmaceuticals by 45.4% during the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock worth $13,601,000 after buying an additional 723,413 shares during the last quarter. Alambic Investment Management L.P. boosted its holdings in Conatus Pharmaceuticals by 207.0% during the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 178,461 shares during the last quarter. Bank of America Corp DE boosted its holdings in Conatus Pharmaceuticals by 75.7% during the second quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock worth $602,000 after buying an additional 60,604 shares during the last quarter. Paloma Partners Management Co bought a new position in Conatus Pharmaceuticals during the second quarter worth about $547,000. Finally, JPMorgan Chase & Co. raised its position in shares of Conatus Pharmaceuticals by 1,205.7% during the first quarter. JPMorgan Chase & Co. now owns 74,062 shares of the biotechnology company’s stock worth $435,000 after purchasing an additional 68,390 shares during the period. Hedge funds and other institutional investors own 33.47% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Article: Bond
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.